Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | See "Remarks" | May 01, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 80,760 |
Reported balance
After 2026-05-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-01 · Sale · Disposed 144,180 · Balance 80,760 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 99,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,601 Underlying: Ordinary Shares · 99,601 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 50,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014440 · doc4.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F4 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014440 · doc4.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,599 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 50,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014440 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014440 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 50,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007953 · doc4.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,242 Underlying: Ordinary Shares · 50,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · derivative · entry 7 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,293 Underlying: Ordinary Shares · 23,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 134,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · derivative · entry 6 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,048 Underlying: Ordinary Shares · 134,048 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 43,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 43,358 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F4 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,921 Underlying: Ordinary Shares · 15,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 43,358 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017056 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:50 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014472 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,197 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023 and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:50 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014472 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008416 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 15,523 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F3 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 15,523 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008416 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 43,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008416 · doc4.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,358 Underlying: Ordinary Shares · 43,358 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F4 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. Read SEC document |
| May 11, 2021 Filed May 13, 2021 11:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032253 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F3 · derivative.expiration_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 11, 2021 Filed May 13, 2021 11:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 37,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-032253 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 20:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 127,244 | $11.22 | $1,427,614.06 |
DisclosureSEC source: 0001209191-21-021298 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,598 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.1800 to $11.2750, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 95,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018529 · doc4.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,057 Underlying: Ordinary Shares · 95,057 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018529 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,841 Underlying: Ordinary Shares · 15,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018529 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015855 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,795 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015855 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011246 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F3 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011246 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009642 · doc4.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,884 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F6 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009642 · doc4.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,523 Underlying: Ordinary Shares · 15,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 65,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009642 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,612 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009642 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 82,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014854 · doc4.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,393 Underlying: Ordinary Shares · 82,393 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 19,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009880 · doc4.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F5 · derivative.expiration_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009880 · doc4.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,712 Underlying: Ordinary Shares · 5,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F4 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009880 · doc4.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 19,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009880 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 72,130.5421 | $13.03 | $939,759.98 |
DisclosureSEC source: 0001209191-20-009880 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.8525 to $13.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 19,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009050 · doc4.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,040 Underlying: Ordinary Shares · 19,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008167 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,046 Underlying: Ordinary Shares · 15,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F3 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008167 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" below 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,130.5421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:26 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 47,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017235 · doc4.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,761 Underlying: Ordinary Shares · 47,761 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010839 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,422 Underlying: Ordinary Shares · 5,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F3 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-010839 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,607.5421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 9,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009987 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,897.5421 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 13:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,000 | $20.52 | $61,560.00 |
DisclosureSEC source: 0001209191-18-011097 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,516.5421 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.54 to $20.50. Read SEC document |
| February 14, 2018 Filed Feb 20, 2018 13:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,050 | $18.45 | $37,822.50 |
DisclosureSEC source: 0001209191-18-011097 · doc4.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,516.5421 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.43 to $18.47. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:30 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 46,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009216 · doc4.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,569 Underlying: Ordinary Shares · 46,569 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 15,523 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:30 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 118,724 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009216 · doc4.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,724 Underlying: Ordinary Shares · 118,724 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 39,574 vesting on each of February 9, 2020 and February 9, 2021 and 39,576 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.